Global Blood Glucose Monitoring Devices Market to reach USD 21.11 billion by 2027.
Global Blood Glucose Monitoring Devices Market is valued approximately at USD 12.64 Billion in 2020 and is anticipated to grow with a healthy growth rate of more than 7.60% over the forecast period 2021-2027. Blood Glucose Monitoring Devices are widely used by the patients suffering from diabetes as well as for the preventive care in other patients. The global Blood Glucose Monitoring Devices market is being driven by the rising number of diabetic patients worldwide. For instance, according to the World Health Organization, in 2019, around 1.5 million deaths occurred due to diabetes directly. The market growth is further propelled by the product launches with new technologies. For instance, in 2021, Essence SmartCare, launched VitalOn, the remote patient monitoring (RPM) solution. Also, in 2021, One Drop announced to launch biosensor device for continuous glucose monitoring for Type 1 and Type 2 diabetes, prediabetes as well as other chronic diseases patients. Furthermore, the unhealthy food consuming habits requires for the self-monitoring of blood glucose level regularly, low physical activities by senior citizens and the technological advancements in the device will provide new opportunities for the global Blood Glucose Monitoring Devices industry. However, inadequate reimbursement and high cost of continuous glucose monitoring (CGM) systems may impede market growth over the forecast period of 2021-2027.

The major regions Asia Pacific, North America, Europe, Latin America, and Rest of the World are evaluated for the regional analysis of the global Blood Glucose Monitoring Devices Market. North America is the leading region across the world in terms of market share due to growing geriatric population and well established healthcare infrastructure with the presence of large companies have stimulated product demand in the region. Whereas Asia-Pacific is anticipated to exhibit the highest CAGR over the forecast period 2021-2027 due to the rising diabetic patients, unhealthy food habits and increase in investments by the large companies in the region.

Major market player included in this report are:
Abbott Laboratories
Medtronic plc
F. Hoffmann-La Roche Ltd.
Bayer AG
Lifescan, Inc.
Dexcom, Inc.
Sanofi
Eli Lilly and Company
B Braun Melsungen AG
ARKRAY, Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product Type:
Self-monitoring Devices
Continuous Devices
By End-Use:
Hospitals
Home Care
Diagnostic Centers

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019
Base year - 2020
Forecast period - 2021 to 2027.

Target Audience of the Global Blood Glucose Monitoring Devices Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors